Hemogenyx Pharmaceuticals PLC announces Total Voting Rights
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Hemogenyx Pharmaceuticals has reported that as of May 28, 2021, its total issued share capital stands at 979,749,321 ordinary shares of 1 pence each, with no shares held in treasury. This figure represents the total number of voting rights in the company. Shareholders are advised to use this number as a denominator for any calculations regarding their investment obligations under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Positive
- Total issued share capital is reported at 979,749,321 ordinary shares, ensuring clarity in voting rights for shareholders.
Negative
- None.
Details
News Market Reaction – HOPHF
The recorded move for HOPHF in the trading session of this news was -72.73%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON, UK / ACCESSWIRE / May 28, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 28 May 2021 consists of 979,749,321 ordinary shares of 1 pence each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 979,749,321.
The figure of 979,749,321 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow | |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View source version on accesswire.com:
https://www.accesswire.com/649566/Hemogenyx-Pharmaceuticals-PLC-announces-Total-Voting-Rights
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.